Co-Authors
This is a "connection" page, showing publications co-authored by Ralph D'Agostino and Stephen Tatter.
Connection Strength
0.227
-
Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D'Agostino RB, Hinckley J, Tatter SB, Dickinson PJ, Debinski W. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro Oncol. 2021 03 25; 23(3):422-434.
Score: 0.049
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.047
-
Sharma P, Sonawane P, Herpai D, D'Agostino R, Rossmeisl J, Tatter S, Debinski W. Multireceptor targeting of glioblastoma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa107.
Score: 0.047
-
McTyre ER, Soike MH, Farris M, Ayala-Peacock DN, Hepel JT, Page BR, Shen C, Kleinberg L, Contessa JN, Corso C, Chiang V, Henson-Masters A, Cramer CK, Ruiz J, Pasche B, Watabe K, D'Agostino R, Su J, Laxton AW, Tatter SB, Fiveash JB, Ahluwalia M, Kotecha R, Chao ST, Braunstein SE, Attia A, Chung C, Chan MD. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiother Oncol. 2020 01; 142:168-174.
Score: 0.044
-
Shenker RF, McTyre ER, Taksler GB, D'Agostino RB, Cramer CK, Ruiz J, Alphonse-Sullivan NK, Farris M, Watabe K, Xing F, Laxton AW, Tatter SB, Chan MD. Analysis of the drivers of cost of management when patients with brain metastases are treated with upfront radiosurgery. Clin Neurol Neurosurg. 2019 01; 176:10-14.
Score: 0.041